Themis Medicare Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
THEMISMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved in line with Nifty Microcap 250 and 0.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Themis Medicare reported its Q3 FY26 (Oct-Dec 2025) unaudited results. Standalone revenue from operations came in at Rs. 9,013.32 lakhs, down about 4% YoY, while nine-month revenue fell roughly 20% to Rs. 26,570.50 lakhs. Standalone Q3 profit after tax rose to Rs. 457.81 lakhs (vs Rs. 308.12 lakhs a year ago), but the nine-month figure swung to a loss of Rs. 1,615.11 lakhs, hurt by a one-time Rs. 129.39 lakh write-off of a UK subsidiary and an Rs. 86.53 lakh impact from new Labour Codes. On a consolidated basis, Q3 PAT jumped to Rs. 1,009.36 lakhs supported by associate/JV income, though the nine-month consolidated result was also a loss of Rs. 774.17 lakhs. The board cleared a preferential issue of convertible warrants to promoter group entities (up to 4.99% / 45.95 lakh shares) and approved an internal transfer of up to 3% of Gujarat Themis Biosyn shares among promoter entities at market price. Company Secretary Pradeep Chandan resigned and was replaced by Nagraj Mogaveera as interim KMP.
The weak nine-month numbers and revenue decline are likely to weigh on sentiment, though quarterly profit recovery and promoter infusion via warrants could provide some support. Existing shareholders face potential dilution of up to ~5% if the warrants are eventually converted, though pricing and terms are yet to be decided.